CJC-1295 + Ipamorelin Blend combines a long-acting GHRH analog with a selective GHRP for synergistic growth hormone release. Our current lot, CP1026Aa01, by Janoshik Analytical (report 101366)
Lot CP1026Aa01
Tested on the 5.61 mg vial
Measured
Figures copied exactly from Janoshik Analytical's report #101366.
Catalog no. PH-CJCIPA-001Size 5MG/5MGMW (reference) BlendMechanism CJC-1295 + Ipamorelin
CJC-1295 + Ipamorelin Blend combines a long-acting GHRH analog with a selective GHRP for synergistic growth hormone release. This combination produces amplified, sustained GH elevation.
Mechanism of Action
CJC-1295 is a tetrasubstituted form of GHRH(1-29) that produces dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more after a single injection (Teichman et al., 2006). Ipamorelin is the first selective growth hormone secretagogue, displaying high GH releasing potency without releasing ACTH or cortisol—a selectivity for GH release similar to that displayed by GHRH (Raun et al., 1998). The combination produces synergistic amplification of pulsatile GH release.
Research Applications
Product Specifications
References
CJC-1295 + Ipamorelin Blend is supplied as a lyophilized powder. Keep it sealed, dry, and away from light until reconstitution.
Lyophilized material is stable when frozen. Once reconstituted, keep it cold and minimise handling to preserve integrity.
CJC-1295 + Ipamorelin Blend is a synthetic peptide compound used in laboratory research settings. Researchers studying growth hormone releasing hormone pathways use this compound to investigate cellular signaling pathways, receptor binding affinities, and structure-activity relationships. Its available Certificate of Analysis documents the reported laboratory results.
CJC-1295 + Ipamorelin Blend is a research compound supplied for in-vitro laboratory use. Mechanism class: CJC-1295 + Ipamorelin. Supplied for growth hormone releasing laboratory research. A third-party Certificate of Analysis is published for the current lot. Research Use Only — not for human or veterinary use.
The current Janoshik Analytical report for CJC-1295 + Ipamorelin Blend (101366) measures content per vial; it does not print an HPLC purity figure.
Yes. Janoshik Analytical report 101366 for CJC-1295 + Ipamorelin Blend is on our COA page, with a link to the lab's own report.
CJC-1295 + Ipamorelin Blend is supplied as a lyophilized powder. Store it at −20°C or below, protected from light and moisture — lyophilized material is stable frozen. Once reconstituted, keep it refrigerated and avoid freeze-thaw cycles.
Orders ship at a $15 flat rate, free on orders of $200 or more, in discreet, insulated packaging. Domestic delivery takes 2–3 business days — 2-day across California, nearby Nevada, and on orders of $250+.
No. CJC-1295 + Ipamorelin Blend is supplied strictly for in-vitro laboratory research. It is not for human or veterinary use, consumption, or diagnostic or clinical applications.
Open the lab report link on our certificate page — it goes to Janoshik Analytical's own verification portal, not a file we host, so the result can't be edited by us. Confirm the report ID (101366) and figures match what's shown here.
The 5MG/5MG size of CJC-1295 + Ipamorelin Blend is $21.00 per mg. See the size selector above for per-mg pricing on every available size.
